<?xml version="1.0" encoding="UTF-8"?>
<!-- This sitemap was dynamically generated on October 21, 2026 at 12:37 PM by All in One SEO v5.0.3 - the original SEO plugin for WordPress. -->

<?xml-stylesheet type="text/xsl" href="https://cgxpwire.com/default-sitemap.xsl"?>

<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
	<channel>
		<title>cGxP.wire</title>
		<link><![CDATA[https://cgxpwire.com]]></link>
		<description><![CDATA[cGxP.wire]]></description>
		<lastBuildDate><![CDATA[Wed, 21 Oct 2026 05:38:32 +0000]]></lastBuildDate>
		<docs>https://validator.w3.org/feed/docs/rss2.html</docs>
		<atom:link href="https://cgxpwire.com/sitemap.rss" rel="self" type="application/rss+xml" />
		<ttl><![CDATA[60]]></ttl>

		<item>
			<guid><![CDATA[https://cgxpwire.com/revolution-medicines-starts-phase-3-trial-of-zoldonrasib-in-nsclc/]]></guid>
			<link><![CDATA[https://cgxpwire.com/revolution-medicines-starts-phase-3-trial-of-zoldonrasib-in-nsclc/]]></link>
			<title>Revolution Medicines Starts Phase 3 Trial of Zoldonrasib in NSCLC</title>
			<pubDate><![CDATA[Wed, 21 Oct 2026 05:38:32 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/cannabix-delivers-breath-based-multi-drug-testing-panel/]]></guid>
			<link><![CDATA[https://cgxpwire.com/cannabix-delivers-breath-based-multi-drug-testing-panel/]]></link>
			<title>Cannabix Delivers Breath-Based Multi-Drug Testing Panel</title>
			<pubDate><![CDATA[Wed, 21 Oct 2026 05:33:46 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/omada-health-study-shows-improved-weight-loss-with-glp-1-care/]]></guid>
			<link><![CDATA[https://cgxpwire.com/omada-health-study-shows-improved-weight-loss-with-glp-1-care/]]></link>
			<title>Omada Health Study Shows Improved Weight Loss With GLP-1 Care</title>
			<pubDate><![CDATA[Wed, 21 Oct 2026 05:30:25 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/itm-reports-radiopharmaceutical-data-at-eanm-2026/]]></guid>
			<link><![CDATA[https://cgxpwire.com/itm-reports-radiopharmaceutical-data-at-eanm-2026/]]></link>
			<title>ITM Reports Radiopharmaceutical Data at EANM 2026</title>
			<pubDate><![CDATA[Wed, 21 Oct 2026 05:24:08 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/hutchmed-closes-1-185b-gsk-license-deal-for-hmpl-a830/]]></guid>
			<link><![CDATA[https://cgxpwire.com/hutchmed-closes-1-185b-gsk-license-deal-for-hmpl-a830/]]></link>
			<title>HUTCHMED Closes $1.185B GSK License Deal for HMPL-A830</title>
			<pubDate><![CDATA[Wed, 21 Oct 2026 05:15:47 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/astrazeneca-to-present-phase-iii-cancer-survival-data-at-esmo-2026/]]></guid>
			<link><![CDATA[https://cgxpwire.com/astrazeneca-to-present-phase-iii-cancer-survival-data-at-esmo-2026/]]></link>
			<title>AstraZeneca to Present Phase III Cancer Survival Data at ESMO 2026</title>
			<pubDate><![CDATA[Wed, 21 Oct 2026 05:09:17 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/veradermics-reports-positive-phase-3-results-for-oral-hair-loss-drug/]]></guid>
			<link><![CDATA[https://cgxpwire.com/veradermics-reports-positive-phase-3-results-for-oral-hair-loss-drug/]]></link>
			<title>Veradermics Reports Positive Phase 3 Results for Oral Hair Loss Drug</title>
			<pubDate><![CDATA[Wed, 21 Oct 2026 05:05:34 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/summit-therapeutics-opens-phase-ii-trial-of-ivonescimab-in-kidney-cancer/]]></guid>
			<link><![CDATA[https://cgxpwire.com/summit-therapeutics-opens-phase-ii-trial-of-ivonescimab-in-kidney-cancer/]]></link>
			<title>Summit Therapeutics Opens Phase II Trial of Ivonescimab in Kidney Cancer</title>
			<pubDate><![CDATA[Wed, 21 Oct 2026 05:02:03 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/united-therapeutics-advances-treprostinil-smi-trial-for-ph-copd/]]></guid>
			<link><![CDATA[https://cgxpwire.com/united-therapeutics-advances-treprostinil-smi-trial-for-ph-copd/]]></link>
			<title>United Therapeutics Advances Treprostinil SMI Trial for PH-COPD</title>
			<pubDate><![CDATA[Wed, 21 Oct 2026 04:58:42 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/trigemx-bio-announces-spac-merger-to-advance-migraine-drug/]]></guid>
			<link><![CDATA[https://cgxpwire.com/trigemx-bio-announces-spac-merger-to-advance-migraine-drug/]]></link>
			<title>TriGemX Bio Announces SPAC Merger to Advance Migraine Drug</title>
			<pubDate><![CDATA[Wed, 21 Oct 2026 04:40:05 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/genentech-to-present-key-oncology-data-at-esmo-2026/]]></guid>
			<link><![CDATA[https://cgxpwire.com/genentech-to-present-key-oncology-data-at-esmo-2026/]]></link>
			<title>Genentech to Present Key Oncology Data at ESMO 2026</title>
			<pubDate><![CDATA[Wed, 21 Oct 2026 04:28:53 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/takeda-reports-verdict-trial-results-for-entyvio-in-ulcerative-colitis/]]></guid>
			<link><![CDATA[https://cgxpwire.com/takeda-reports-verdict-trial-results-for-entyvio-in-ulcerative-colitis/]]></link>
			<title>Takeda Reports VERDICT Trial Results for ENTYVIO in Ulcerative Colitis</title>
			<pubDate><![CDATA[Wed, 21 Oct 2026 04:26:01 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/zealand-pharma-reports-positive-phase-1-results-for-zp9830/]]></guid>
			<link><![CDATA[https://cgxpwire.com/zealand-pharma-reports-positive-phase-1-results-for-zp9830/]]></link>
			<title>Zealand Pharma Reports Positive Phase 1 Results for ZP9830</title>
			<pubDate><![CDATA[Wed, 21 Oct 2026 04:22:24 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/oculis-completes-predict-1-randomization-for-dry-eye-drug/]]></guid>
			<link><![CDATA[https://cgxpwire.com/oculis-completes-predict-1-randomization-for-dry-eye-drug/]]></link>
			<title>Oculis Completes PREDICT-1 Randomization for Dry Eye Drug</title>
			<pubDate><![CDATA[Wed, 21 Oct 2026 04:20:11 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/evaxion-reports-three-year-evx-01-melanoma-vaccine-results/]]></guid>
			<link><![CDATA[https://cgxpwire.com/evaxion-reports-three-year-evx-01-melanoma-vaccine-results/]]></link>
			<title>Evaxion Reports Three-Year EVX-01 Melanoma Vaccine Results</title>
			<pubDate><![CDATA[Wed, 21 Oct 2026 04:17:28 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/immunitybio-reports-long-term-anktiva-data-in-bladder-cancer/]]></guid>
			<link><![CDATA[https://cgxpwire.com/immunitybio-reports-long-term-anktiva-data-in-bladder-cancer/]]></link>
			<title>ImmunityBio Reports Long-Term ANKTIVA Data in Bladder Cancer</title>
			<pubDate><![CDATA[Mon, 19 Oct 2026 04:28:34 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/alcon-wins-fda-approval-for-brytly-redness-relief-eye-drops/]]></guid>
			<link><![CDATA[https://cgxpwire.com/alcon-wins-fda-approval-for-brytly-redness-relief-eye-drops/]]></link>
			<title>Alcon Wins FDA Approval for BRYTLY Redness-Relief Eye Drops</title>
			<pubDate><![CDATA[Mon, 19 Oct 2026 04:25:41 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/opus-genetics-wins-fda-approval-for-ryzumvi-in-presbyopia/]]></guid>
			<link><![CDATA[https://cgxpwire.com/opus-genetics-wins-fda-approval-for-ryzumvi-in-presbyopia/]]></link>
			<title>Opus Genetics Wins FDA Approval for RYZUMVI in Presbyopia</title>
			<pubDate><![CDATA[Mon, 19 Oct 2026 04:20:05 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/organon-reports-positive-six-year-miudella-phase-3-results/]]></guid>
			<link><![CDATA[https://cgxpwire.com/organon-reports-positive-six-year-miudella-phase-3-results/]]></link>
			<title>Organon Reports Positive Six-Year MIUDELLA Phase 3 Results</title>
			<pubDate><![CDATA[Mon, 19 Oct 2026 04:16:57 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/tiziana-completes-dosing-initiation-in-phase-2-alzheimers-trial/]]></guid>
			<link><![CDATA[https://cgxpwire.com/tiziana-completes-dosing-initiation-in-phase-2-alzheimers-trial/]]></link>
			<title>Tiziana Completes Dosing Initiation in Phase 2 Alzheimer’s Trial</title>
			<pubDate><![CDATA[Mon, 19 Oct 2026 04:13:24 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/regenerons-libtayo-recommended-for-updated-eu-dosing-regimen/]]></guid>
			<link><![CDATA[https://cgxpwire.com/regenerons-libtayo-recommended-for-updated-eu-dosing-regimen/]]></link>
			<title>Regeneron’s Libtayo Recommended for Updated EU Dosing Regimen</title>
			<pubDate><![CDATA[Mon, 19 Oct 2026 04:10:39 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/genentech-wins-fda-approval-for-enspryng-in-thyroid-eye-disease/]]></guid>
			<link><![CDATA[https://cgxpwire.com/genentech-wins-fda-approval-for-enspryng-in-thyroid-eye-disease/]]></link>
			<title>Genentech Wins FDA Approval for Enspryng in Thyroid Eye Disease</title>
			<pubDate><![CDATA[Mon, 19 Oct 2026 04:08:04 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/ionis-pharmaceuticals-wins-eu-chmp-support-for-tryngolza-in-shtg/]]></guid>
			<link><![CDATA[https://cgxpwire.com/ionis-pharmaceuticals-wins-eu-chmp-support-for-tryngolza-in-shtg/]]></link>
			<title>Ionis Pharmaceuticals Wins EU CHMP Support for TRYNGOLZA in sHTG</title>
			<pubDate><![CDATA[Mon, 19 Oct 2026 04:04:59 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/cellectar-biosciences-reports-strong-iopofosine-phase-2b-results/]]></guid>
			<link><![CDATA[https://cgxpwire.com/cellectar-biosciences-reports-strong-iopofosine-phase-2b-results/]]></link>
			<title>Cellectar Biosciences Reports Strong Iopofosine Phase 2b Results</title>
			<pubDate><![CDATA[Mon, 19 Oct 2026 04:01:47 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/aquestive-therapeutics-wins-fda-acceptance-for-anaphylm-nda-resubmission/]]></guid>
			<link><![CDATA[https://cgxpwire.com/aquestive-therapeutics-wins-fda-acceptance-for-anaphylm-nda-resubmission/]]></link>
			<title>Aquestive Therapeutics Wins FDA Acceptance for Anaphylm NDA Resubmission</title>
			<pubDate><![CDATA[Mon, 19 Oct 2026 03:58:34 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/eikon-therapeutics-submits-ind-for-prostate-cancer-drug-eik1006/]]></guid>
			<link><![CDATA[https://cgxpwire.com/eikon-therapeutics-submits-ind-for-prostate-cancer-drug-eik1006/]]></link>
			<title>Eikon Therapeutics Submits IND for Prostate Cancer Drug EIK1006</title>
			<pubDate><![CDATA[Mon, 19 Oct 2026 03:55:36 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/nrx-pharmaceuticals-receives-fda-labeling-review-letter/]]></guid>
			<link><![CDATA[https://cgxpwire.com/nrx-pharmaceuticals-receives-fda-labeling-review-letter/]]></link>
			<title>NRx Pharmaceuticals Receives FDA Labeling Review Letter</title>
			<pubDate><![CDATA[Mon, 19 Oct 2026 03:52:46 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/legend-biotech-wins-fda-ind-clearance-for-lb2501-in-vivo-car-t/]]></guid>
			<link><![CDATA[https://cgxpwire.com/legend-biotech-wins-fda-ind-clearance-for-lb2501-in-vivo-car-t/]]></link>
			<title>Legend Biotech Wins FDA IND Clearance for LB2501 In Vivo CAR-T</title>
			<pubDate><![CDATA[Mon, 19 Oct 2026 03:51:57 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/opus-genetics-reports-positive-gene-therapy-data-in-2026/]]></guid>
			<link><![CDATA[https://cgxpwire.com/opus-genetics-reports-positive-gene-therapy-data-in-2026/]]></link>
			<title>Opus Genetics Reports Positive Gene Therapy Data in 2026</title>
			<pubDate><![CDATA[Mon, 19 Oct 2026 03:44:38 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/macrogenics-doses-first-patient-in-mgc030-phase-1-trial/]]></guid>
			<link><![CDATA[https://cgxpwire.com/macrogenics-doses-first-patient-in-mgc030-phase-1-trial/]]></link>
			<title>MacroGenics Doses First Patient in MGC030 Phase 1 Trial</title>
			<pubDate><![CDATA[Mon, 19 Oct 2026 03:40:49 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/spectrum-dynamics-advances-all-energy-digital-spect-ct/]]></guid>
			<link><![CDATA[https://cgxpwire.com/spectrum-dynamics-advances-all-energy-digital-spect-ct/]]></link>
			<title>Spectrum Dynamics Advances All-Energy Digital SPECT/CT</title>
			<pubDate><![CDATA[Mon, 19 Oct 2026 03:14:39 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/simbiosys-wins-fda-clearance-for-ai-breast-cancer-risk-tool/]]></guid>
			<link><![CDATA[https://cgxpwire.com/simbiosys-wins-fda-clearance-for-ai-breast-cancer-risk-tool/]]></link>
			<title>SimBioSys Wins FDA Clearance for AI Breast Cancer Risk Tool</title>
			<pubDate><![CDATA[Mon, 19 Oct 2026 03:13:33 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/transpirebio-ceo-highlights-fda-generic-inhaler-framework/]]></guid>
			<link><![CDATA[https://cgxpwire.com/transpirebio-ceo-highlights-fda-generic-inhaler-framework/]]></link>
			<title>TranspireBio CEO Highlights FDA Generic Inhaler Framework</title>
			<pubDate><![CDATA[Mon, 19 Oct 2026 03:13:01 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/marengo-wins-second-fda-fast-track-for-invikafusp-alfa/]]></guid>
			<link><![CDATA[https://cgxpwire.com/marengo-wins-second-fda-fast-track-for-invikafusp-alfa/]]></link>
			<title>Marengo Wins Second FDA Fast Track for Invikafusp Alfa</title>
			<pubDate><![CDATA[Mon, 19 Oct 2026 03:12:26 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/philips-launches-exit-cvd-studies-to-advance-heart-care/]]></guid>
			<link><![CDATA[https://cgxpwire.com/philips-launches-exit-cvd-studies-to-advance-heart-care/]]></link>
			<title>Philips Launches EXIT-CVD Studies to Advance Heart Care</title>
			<pubDate><![CDATA[Mon, 19 Oct 2026 03:11:39 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/elevar-resubmits-fda-application-for-liver-cancer-therapy/]]></guid>
			<link><![CDATA[https://cgxpwire.com/elevar-resubmits-fda-application-for-liver-cancer-therapy/]]></link>
			<title>Elevar Resubmits FDA Application for Liver Cancer Therapy</title>
			<pubDate><![CDATA[Mon, 19 Oct 2026 03:11:02 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/sab-bio-wins-fda-fast-track-for-sab-142-diabetes-therapy/]]></guid>
			<link><![CDATA[https://cgxpwire.com/sab-bio-wins-fda-fast-track-for-sab-142-diabetes-therapy/]]></link>
			<title>SAB BIO Wins FDA Fast Track for SAB-142 Diabetes Therapy</title>
			<pubDate><![CDATA[Mon, 19 Oct 2026 03:10:14 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/takeda-reports-positive-tak-881-phase-2-3-trial-results/]]></guid>
			<link><![CDATA[https://cgxpwire.com/takeda-reports-positive-tak-881-phase-2-3-trial-results/]]></link>
			<title>Takeda Reports Positive TAK-881 Phase 2/3 Trial Results</title>
			<pubDate><![CDATA[Mon, 19 Oct 2026 03:09:23 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/vanda-pharmaceuticals-reports-vqw-765-phase-iii-results/]]></guid>
			<link><![CDATA[https://cgxpwire.com/vanda-pharmaceuticals-reports-vqw-765-phase-iii-results/]]></link>
			<title>Vanda Pharmaceuticals Reports VQW-765 Phase III Results</title>
			<pubDate><![CDATA[Mon, 19 Oct 2026 03:08:46 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/cu-anschutz-study-shows-cgm-benefits-in-type-2-diabetes/]]></guid>
			<link><![CDATA[https://cgxpwire.com/cu-anschutz-study-shows-cgm-benefits-in-type-2-diabetes/]]></link>
			<title>CU Anschutz Study Shows CGM Benefits in Type 2 Diabetes</title>
			<pubDate><![CDATA[Mon, 19 Oct 2026 03:08:12 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/enliven-therapeutics-names-kristine-ball-to-board-leadership/]]></guid>
			<link><![CDATA[https://cgxpwire.com/enliven-therapeutics-names-kristine-ball-to-board-leadership/]]></link>
			<title>Enliven Therapeutics Names Kristine Ball to Board Leadership</title>
			<pubDate><![CDATA[Mon, 19 Oct 2026 03:07:23 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/alvotech-and-advanz-file-eylea-8-mg-biosimilar-application/]]></guid>
			<link><![CDATA[https://cgxpwire.com/alvotech-and-advanz-file-eylea-8-mg-biosimilar-application/]]></link>
			<title>Alvotech and Advanz File Eylea 8 mg Biosimilar Application</title>
			<pubDate><![CDATA[Mon, 19 Oct 2026 03:06:48 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/phanes-therapeutics-doses-first-crc-patient-with-spevatamig/]]></guid>
			<link><![CDATA[https://cgxpwire.com/phanes-therapeutics-doses-first-crc-patient-with-spevatamig/]]></link>
			<title>Phanes Therapeutics Doses First CRC Patient With Spevatamig</title>
			<pubDate><![CDATA[Mon, 19 Oct 2026 03:05:25 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/enodia-therapeutics-and-pfizer-sign-500m-drug-discovery-deal/]]></guid>
			<link><![CDATA[https://cgxpwire.com/enodia-therapeutics-and-pfizer-sign-500m-drug-discovery-deal/]]></link>
			<title>Enodia Therapeutics and Pfizer Sign $500M Drug Discovery Deal</title>
			<pubDate><![CDATA[Mon, 19 Oct 2026 03:04:49 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/oncolytics-biotech-updates-goblet-cancer-study-data-timeline/]]></guid>
			<link><![CDATA[https://cgxpwire.com/oncolytics-biotech-updates-goblet-cancer-study-data-timeline/]]></link>
			<title>Oncolytics Biotech Updates GOBLET Cancer Study Data Timeline</title>
			<pubDate><![CDATA[Mon, 19 Oct 2026 03:04:02 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/crescent-biopharma-advances-cr-001-and-adc-cancer-pipeline/]]></guid>
			<link><![CDATA[https://cgxpwire.com/crescent-biopharma-advances-cr-001-and-adc-cancer-pipeline/]]></link>
			<title>Crescent Biopharma Advances CR-001 and ADC Cancer Pipeline</title>
			<pubDate><![CDATA[Sat, 17 Oct 2026 05:12:03 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/leads-biolabs-doses-first-patient-in-colorectal-cancer-trial/]]></guid>
			<link><![CDATA[https://cgxpwire.com/leads-biolabs-doses-first-patient-in-colorectal-cancer-trial/]]></link>
			<title>Leads Biolabs Doses First Patient in Colorectal Cancer Trial</title>
			<pubDate><![CDATA[Sat, 17 Oct 2026 05:09:03 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/roche-wins-fda-approval-for-enspryng-in-thyroid-eye-disease/]]></guid>
			<link><![CDATA[https://cgxpwire.com/roche-wins-fda-approval-for-enspryng-in-thyroid-eye-disease/]]></link>
			<title>Roche Wins FDA Approval for Enspryng in Thyroid Eye Disease</title>
			<pubDate><![CDATA[Sat, 17 Oct 2026 05:06:12 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/insitro-and-astrazeneca-partner-on-ai-drug-discovery/]]></guid>
			<link><![CDATA[https://cgxpwire.com/insitro-and-astrazeneca-partner-on-ai-drug-discovery/]]></link>
			<title>insitro and AstraZeneca Partner on AI Drug Discovery</title>
			<pubDate><![CDATA[Sat, 17 Oct 2026 05:03:00 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/kedrion-calls-for-earlier-diagnosis-of-immune-deficiencies/]]></guid>
			<link><![CDATA[https://cgxpwire.com/kedrion-calls-for-earlier-diagnosis-of-immune-deficiencies/]]></link>
			<title>Kedrion Calls for Earlier Diagnosis of Immune Deficiencies</title>
			<pubDate><![CDATA[Sat, 17 Oct 2026 05:02:11 +0000]]></pubDate>
		</item>
				</channel>
</rss>
